Company intelligence / Profile preview

Poolbeg Pharma

London, N/A, United Kingdompoolbegpharma.com ↗

Ownership: Public · POLB
Employees: ~15
Development stage: Phase 2

Overview

Lead program POLB001 has completed or is undergoing Phase I trials for CRS/severe influenza. Other programs include an oral GLP‑1R agonist for obesity/diabetes, a broad-spectrum RNA-based therapy for respiratory viruses, an intramuscular melioidosis vaccine, plus AI-driven infectious disease programs. No pivotal efficacy results disclosed as of May 2025.

Therapeutic areas: Metabolic DisordersOncologyRare DiseasesInfectious Diseases
Modalities: Small molecules (e.g., POLB001)RNA-based immunotherapy (POLB002)Oral encapsulated GLP‑1 receptor agonistsIntramuscular vaccines
Industry: Biotech

Drug pipeline

5 assets

POLB 001

4 more assets in the full pipeline.

Request access →

Partnerships

Inlicensed technology partners for encapsulation/vaccine delivery platforms.

Beyond the preview

Go deeper on Poolbeg Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poolbeg Pharma.

Explore the full profile